In vitro-induced response patterns of antileukemic T cells: characterization by spectratyping and immunophenotyping
- PMID: 22441559
- DOI: 10.1007/s10238-012-0180-y
In vitro-induced response patterns of antileukemic T cells: characterization by spectratyping and immunophenotyping
Abstract
Myeloid leukemic cells can be induced to differentiate into leukemia-derived dendritic cells (DCleu) regaining the stimulatory capacity of professional DCs while presenting the leukemic antigen repertoire. But so far, the induced antileukemic T-cell responses are variable both in specificity and in efficacy. In an attempt to elucidate the underlying causes of different T-cell response patterns, T-cell receptor (TR) Vβ chain rearrangements were correlated with the T cells corresponding immunophenotypic profile, as well as their proliferative response and cytolytic capacities. In three different settings, donor T cells, either human leukocyte antigen matched or mismatched (haploidentical), or autologous T cells were repeatedly stimulated with myeloid blasts or leukemia-derived DC/DCleus from the corresponding patients diseased from acute myeloid leukemia (AML). Although no significant differences in T-cell proliferation were observed, the T-cell-mediated cytolytic response pattern varied considerably and even caused blast proliferation in two cases. Spectratyping revealed a remarkable restriction (>75% of normal level) of the CD4+ or CD8+-TR repertoire of blast- or DC/DCleu-stimulated T cells. Although in absolute terms, DC/DCleu stimulation induced the highest grade of restriction in the CD8+ T-cell subset, the CD4+ T-cell compartment seemed to be relatively more affected. But most importantly, in vitro stimulation with DC/DCleu resulted into an identical TR restriction pattern (β chain) that could be identified in vivo in a patient sample 3 months after allo-SCT. Thus, in vitro tests combining functional flow cytometry with spectratyping might provide predictive information about T cellular response patterns in vivo.
Similar articles
-
Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.Transfus Med Hemother. 2020 Dec;47(6):432-443. doi: 10.1159/000512452. Epub 2020 Nov 5. Transfus Med Hemother. 2020. PMID: 33442338 Free PMC article. Review.
-
Improved effector function of leukemia-specific T-lymphocyte clones trained with AML-derived dendritic cells.Cancer Genomics Proteomics. 2008 Sep-Oct;5(5):275-86. Cancer Genomics Proteomics. 2008. PMID: 19129558
-
Role of Interferon (IFN)α in "Cocktails" for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions.J Immunother. 2019 Jun;42(5):143-161. doi: 10.1097/CJI.0000000000000266. J Immunother. 2019. PMID: 31090655
-
CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT.Immunobiology. 2014 Apr;219(4):247-60. doi: 10.1016/j.imbio.2013.10.008. Epub 2013 Oct 27. Immunobiology. 2014. PMID: 24315637
-
Dendritic cells and T lymphocytes: developmental and functional interactions.Ciba Found Symp. 1997;204:130-8; discussion 138-41. doi: 10.1002/9780470515280.ch9. Ciba Found Symp. 1997. PMID: 9107416 Review.
Cited by
-
Research progress on dendritic cell vaccines in cancer immunotherapy.Exp Hematol Oncol. 2022 Jan 24;11(1):3. doi: 10.1186/s40164-022-00257-2. Exp Hematol Oncol. 2022. PMID: 35074008 Free PMC article. Review.
-
Specificity, Privacy, and Degeneracy in the CD4 T Cell Receptor Repertoire Following Immunization.Front Immunol. 2017 Apr 13;8:430. doi: 10.3389/fimmu.2017.00430. eCollection 2017. Front Immunol. 2017. PMID: 28450864 Free PMC article.
-
Molecular mechanisms augmenting resistance to current therapies in clinics among cervical cancer patients.Med Oncol. 2023 Apr 15;40(5):149. doi: 10.1007/s12032-023-01997-9. Med Oncol. 2023. PMID: 37060468 Free PMC article. Review.
-
Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.Transfus Med Hemother. 2020 Dec;47(6):432-443. doi: 10.1159/000512452. Epub 2020 Nov 5. Transfus Med Hemother. 2020. PMID: 33442338 Free PMC article. Review.
-
Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Front Immunol. 2017 Jun 7;8:496. doi: 10.3389/fimmu.2017.00496. eCollection 2017. Front Immunol. 2017. PMID: 28638379 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials